Kemwell Biopharma

The entry if new biosimilars in the market will not only reduce prices but also increase competition. This new development will help patients get access to innovative medication. However, regulatory burdens and high manufacturing costs make it difficult for biosimilar contract manufacturers to reduce prices to the same extent as generics. On the other hand, there is apprehension among biosimilar manufacturers that reducing prices significantly will eliminate the incentive for them to enter the biosimilar space. Addressing these difficulties presents an opportunity to lower drug costs and improve patient access. What’s the Current Practice? For outpatients, reimbursement for medicines administered by providers is based on the Average Sales Price. Medicare pays the provider Average Sales Price + 6% of the medicine. Due to the lag between published Average Sales Price data and product launch, payers depend on Wholesale Acquisition Cost until the Average Sales Pric...

In this modern technological world, India is getting ahead of many countries in terms of contract manufacturing and various developments.   Due to the high quality of international standards of the medicines available at low costs, India has chosen it with positive mode. It is an innovative and creative technique which can help in matching the changing trends in the field of medicines. It is a really dynamic and transitional field where one has to face lot of challenges and you also need to find out the growth options for it. It can be really possible for India to setup CMOs permanently up to the ground level in the near future. Due to increasing diseases,    the manufacture of drugs is also increasing and that’s why it has become important for the manufacturers to focus on the production of high-quality medicines. There are tight norms for the manufacturing of clinical trials, patents along with research in the medicinal field. The MNCs are really knowledge-based b...

As the APIs are becoming more and more complex, the demand for contract manufacturing is increasing. Most of the biopharmaceutical companies depend on CDMOs and contract development services in order to produce safe and high quality of sterile drugs. The demand for sterile fill finish is increasing and that’s why its manufacturing has become quite important. Specialized equipment and capabilities are necessary for completing complicated tasks. Due to various challenges in the production of these drugs, most of the companies depend on CDMOs in order to manage the proper manufacture of drugs. The smaller companies without any production capabilities depend on the outsourcing partners. Whenever the specialized capabilities are required, then the large companies take the help of contract manufacturing companies. One can definitely believe that CDMOs are a backup source for drug manufacturing companies. It is necessary for the drug pharmaceutical companies to choose the best pa...

Since the past few years, the protein therapeutics are the growth drivers of most of the biopharmaceutical companies. Some of the monoclonal antibody products are able to become one of the best selling medicines in the world. It has become quite challenging to produce biotherapeutics due to its complex and large sized molecules . Due to its fragile nature, manufacturers are forced to change the way they used to handle drug products earlier. The market of biologics is increasing during the past decade and the sales have been increased up to 20%. The living sources are used to extract drugs in case of biopharmaceutical drugs. Cells, nucleic acids, viruses, vaccines are some of the products which are used for the manufacture of these drugs . It might not be much difficult to carry on the production of biologics but these are expensive. Due to complex chains , it carries a lot of cost during the manufacture of these drugs.    The structure of the prot...